Patents by Inventor Hanns-Martin Schmidt
Hanns-Martin Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230400417Abstract: The invention concerns, amongst others, a device (1) for specific illumination of at least one biological sample, the device (1) comprising a multitude of cavities (2), each cavity (2) representing an internal space (3) being capable of holding the biological sample. The internal spaces (3) are each partially surrounded by a wall element (4) comprising windows (5) for observing and/or illuminating the internal spaces (3). In order to protect the internal spaces (3) from the ingress of light, the wall element (4) comprises a light-proof material. Each window (5) comprises at least one switchable element (8) being of switchable color and/or light transmittance. By the switchable elements (8), light exposure of the biological sample in the internal space (3) of each cavity (2) can be controlled so that unintended light exposure can be effectively avoided when illumination of the sample does not occur and/or the device (1) is stored or transported.Type: ApplicationFiled: October 19, 2021Publication date: December 14, 2023Applicant: Ningaloo Biosystems GmbHInventors: Herbert Mueller-Hartmann, Hanns-Martin SCHMIDT
-
Patent number: 11193156Abstract: The present invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins, cell lines that can be used in said methods, respective recombinant glycoproteins, and methods for expressing the same in said cell lines.Type: GrantFiled: March 15, 2018Date of Patent: December 7, 2021Assignee: Cevec Pharmaceutical GmbHInventors: Hanns-Martin Schmidt, Markus Ribbert, Gudrun Schiedner, Silke Wissing, Jens Wölfel
-
Publication number: 20200032311Abstract: The present invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins, cell lines that can be used in said methods, respective recombinant glycoproteins, and methods for expressing the same in said cell lines.Type: ApplicationFiled: March 15, 2018Publication date: January 30, 2020Applicant: Cevec Pharmaceutical GmbHInventors: Hanns-Martin Schmidt, Markus Ribbert, Gudrun Schiedner, Silke Wissing, Jens Wölfel
-
Patent number: 7999073Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.Type: GrantFiled: November 21, 2007Date of Patent: August 16, 2011Assignee: Lonza Cologne GmbHInventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tatjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Tamara Grabek, Andrea Mueller-Hartmann
-
Publication number: 20080220527Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.Type: ApplicationFiled: November 21, 2007Publication date: September 11, 2008Applicant: AMAXA AGInventors: Hanns-Martin SCHMIDT, Ludger ALTROGGE, Dietmar LENZ, Gudula RIEMEN, Helmut BROSTERHUS, Elke LORBACH, Juliana HELFRICH, Katharina HEIN, Marion GREMSE, Tatjana MALES, Rainer CHRISTINE, Gregor SIEBENKOTTEN, Bodo ORTMANN, Tamara GRABECK, Andrea MULLER-HARTMANN
-
Patent number: 7320859Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.Type: GrantFiled: January 10, 2002Date of Patent: January 22, 2008Assignee: Amaxa AGInventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tatjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Tamara Turbanski, Andreas Klaes
-
Publication number: 20040137622Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.Type: ApplicationFiled: August 13, 2003Publication date: July 15, 2004Inventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tarjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Andrea Klacs